Chronic mast cell leukaemia with exon 9 mutation A502_Y503dup: a rare imatinib responsive variant.
作者信息
Manthri Sukesh, Costello Patrick N, Krishnan Koyamangalath
机构信息
Internal Medicine, Division of Medical Oncology, East Tennessee State University, Johnson City, Tennessee, USA
Watauga Pathology, East Tennessee State University, Johnson City, Tennessee, USA.
出版信息
BMJ Case Rep. 2020 Aug 24;13(8):e236447. doi: 10.1136/bcr-2020-236447.
Abstract
摘要
相似文献
1
Chronic mast cell leukaemia with exon 9 mutation A502_Y503dup: a rare imatinib responsive variant.伴有外显子9突变A502_Y503dup的慢性肥大细胞白血病：一种罕见的对伊马替尼敏感的变异型
BMJ Case Rep. 2020 Aug 24;13(8):e236447. doi: 10.1136/bcr-2020-236447.
2
A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.一例伴有外显子 9 KIT 突变的肥大细胞白血病和对伊马替尼良好反应的病例。
Eur J Haematol. 2011 Jun;86(6):531-5. doi: 10.1111/j.1600-0609.2011.01598.x. Epub 2011 Apr 7.
3
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.PKC412抑制表达KIT基因D816V突变变体的人肿瘤性肥大细胞的体外生长：与AMN107、伊马替尼和克拉屈滨（2CdA）比较及联合用药效果评估。
Blood. 2006 Jan 15;107(2):752-9. doi: 10.1182/blood-2005-07-3022. Epub 2005 Sep 27.
4
Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.在犬肥大细胞瘤中鉴定出与伊马替尼耐药相关的KIT激酶结构域中的继发性突变。
Vet Immunol Immunopathol. 2017 Jun;188:84-88. doi: 10.1016/j.vetimm.2017.05.004. Epub 2017 May 13.
5
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.肥大细胞白血病：鉴定一种新的 c-Kit 突变，dup(501-502)，以及对 c-Kit 酪氨酸激酶抑制剂 masitinib 的反应。
Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. Epub 2012 Apr 28.
6
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.伊马替尼剂量递增与舒尼替尼作为KIT外显子11突变型胃肠道间质瘤二线治疗的回顾性分析
Oncotarget. 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136.
7
Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.伊马替尼对一个患有年轻发病的胃肠道间质瘤和与种系KIT-Trp557Arg突变相关的皮肤色素沉着的家族具有显著疗效：病例报告及文献综述
Fam Cancer. 2018 Apr;17(2):247-253. doi: 10.1007/s10689-017-0024-8.
8
Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.胃肠间质瘤患者伊马替尼初治人群中的癌基因突变分析。
Cell Mol Biol (Noisy-le-grand). 2020 Dec 31;66(8):26-32.
9
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.辅助伊马替尼治疗胃肠间质瘤患者中 KIT 和 PDGFRA 突变对生存的影响：一项随机临床试验的探索性分析。
JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.
10
Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.通过细胞凋亡，评估甲磺酸伊马替尼对携带 c-Kit 外显子 11 突变的犬肿瘤肥大细胞诱导细胞死亡的离体评价。
Vet Res Commun. 2013 Jun;37(2):101-8. doi: 10.1007/s11259-013-9550-5. Epub 2013 Jan 13.
本文引用的文献
1
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.中剂量伊马替尼治疗晚期系统性肥大细胞增多症的疗效和安全性。
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
2
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.慢性肥大细胞白血病：一种具有独特形态学和临床特征的新型白血病变体。
Leuk Res. 2015 Jan;39(1):1-5. doi: 10.1016/j.leukres.2014.09.010. Epub 2014 Sep 30.
3
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.肥大细胞白血病（MCL）和髓肥大细胞白血病（MML）的精细诊断标准与分类：一项共识提议。
Ann Oncol. 2014 Sep;25(9):1691-1700. doi: 10.1093/annonc/mdu047. Epub 2014 Mar 27.
4
A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.一例伴有外显子 9 KIT 突变的肥大细胞白血病和对伊马替尼良好反应的病例。
Eur J Haematol. 2011 Jun;86(6):531-5. doi: 10.1111/j.1600-0609.2011.01598.x. Epub 2011 Apr 7.
5
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.甲磺酸伊马替尼治疗系统性肥大细胞增多症：一项II期试验
Cancer. 2006 Jul 15;107(2):345-51. doi: 10.1002/cncr.21996.
Zotero 插件